NORTH AMERICA AND EUROPE ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) MARKET ANALYSIS

North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, by Drug Type (Oral & Parenteral Antibiotics (Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others) and Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), by Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, and Europe) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Nov 2020
Code : CMI4273
Pages :252
Formats :
Excel and PDF
Industry : Pharmaceutical

North America And Europe Acute Bacterial Skin And Skin Structure Infections (ABSSSI) MarketSize and Trends

The ABSSSI market is expected to witness moderate growth owing to the increasing number of patients suffering from skin infections and large number of pipeline products, which are expected to receive approval during the forecast period.

The North America and Europe acute bacterial skin and skin structure infections market is estimated to be valued at US$ 1,283.8 million in 2020 and is expected to exhibit a CAGR of 3.9% during the forecast period (2020-2027).

Figure 1. North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Share (%) Analysis, By Technology, 2020 & 2027

Increasing research and development activities are expected to boost growth of the North America and Europe Acute Bacterial Skin and Skin Structure Infections Market.

Figure 2. North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027